Paroxysmal Nocturnal Hemoglobinuria
Generic Name: eculizumab (E kue LIZ oo mab)
Brand Names: Soliris
Medically reviewed by Sanjai Sinha, MD Last updated on Aug 1, 2019.
What is Soliris?
Soliris (eculizumab) is a monoclonal antibody. Eculizumab binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells.
Soliris is used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria (PNH).
Soliris is also used to treat a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS) in adults and children who weigh at least 11 pounds (5 kilograms).
Soliris is also used to treat myasthenia gravis in adults.
Soliris is also used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults.
Soliris is available only under a special program. You must be registered in the program and understand the risks and benefits of this medicine.
40 kg and over900 mg weekly × 4 doses1200 mg at week 5;
then 1200 mg every 2 weeks30 kg to less than 40 kg600 mg weekly × 2 doses900 mg at week 3;
then 900 mg every 2 weeks20 kg to less than 30 kg600 mg weekly × 2 doses600 mg at week 3;
then 600 mg every 2 weeks10 kg to less than 20 kg600 mg weekly × 1 dose300 mg at week 2;
then 300 mg every 2 weeks5 kg to less than 10 kg300 mg weekly × 1 dose300 mg at week 2;
then 300 mg every 3 weeks
For patients 18 years of age and older, Soliris therapy consists of:
900 mg weekly for the first 4 weeks, followed by
1200 mg for the fifth dose 1 week later, then
1200 mg every 2 weeks thereafter.